Is antisense an appropriate nomenclature or design for oligodeoxynucleotides aimed at the inhibition of hiv-1 replication?

AAPS Journal

Volumn 4, Issue 2, 2002, Pages

  Lavigne, Carole ^a   Yelle, Jocelyn ^b   Sauvé, Gilles ^b   Thierry, Alain R ^c,d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

Fibroblast growth factor; Keratinocyte growth factor; Pharmacokinetics clinical trial; Pharmacology

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE;

ARTICLE; CELL CULTURE; CELL LINE; COMPARATIVE STUDY; CYTOLOGY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; METABOLISM; METHODOLOGY; NOMENCLATURE; PATHOLOGY; SYNTHESIS; T LYMPHOCYTE; VIROLOGY; VIRUS REPLICATION;

ANTI-HIV AGENTS; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; DRUG EVALUATION, PRECLINICAL; HIV INFECTIONS; HIV-1; HUMANS; LEUKEMIA; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; T-LYMPHOCYTES; TERMINOLOGY; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 52449122963     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Stein CA, Tonkinson JL, Yakubov L. Phosphorothioate oligodeoxynucleotides-antisense inhibitors of gene expression? Pharmacol Ther. 1991;52:365-384.
2. Zamecnik PC, Stephenson M. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sei USA. 1978;75:280-284.
3. Zamecnik PC, Goodchild J, Taguchi Y, Sarin PS. Inhibition of replication and expression of human T-cell lymphotropic type III in cultured cells by exogenous synthetic oligonucleotides complementary to viral RNA. Proc Natl Acad Sei USA. 1986;83:4143-4146.
4. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutics agents: is the bullet really magical? Science. 1993;261:1004-1012.
5. Agrawal S, Temsamani J, Tang J-Y. Pharmacokinetics biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sei USA. 1991 ;88:7595-7599.
6. Bennett CF, Dean N, Ecker DJ, Monia BP. Pharmacology of antisense therapeutic agents: cancer and inflammation. In: Agrawal S, ed. Antisense Therapeutics, [city?], NJ: Humana Press; 1996:13-46.
7. Iversen PL, Mata J, Tracewell WG, Zon G. Pharmacokinetics of an antisense phosphorothioate oligodeoxynucleotide against rev from human immunodeficiency virus type 1 in adult male rat following single injections and continuous infusion. Antisense Res Dev. 1994;4:43-52.
8. Agrawal S, Temsamini J, Galbraith W, Tang J-Y. Pharmacokinetics of antisense oligonucleotides. Clin Pharmacokinet. 1995;28:7-16.
9. Roush W. Antisense aims for a renaissance. Science. 1997;276:1192-1193.
10. Wagner RW. The state of the art in antisense research. Nature Medecine. 1995;1:1116-1118.
11. Stein CA, Kreig AM. Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev. 1994;4:67-69.
12. Wagner RW. Gene inhibition using antisense oligodeoxynucleotides. Nature. 1994;372:333-335.
13. Thierry AR, Tackle GB. Liposomes as a delivery system for antisense and rybozyme compounds. In: Akhtar S, ed. Delivery Strategies for Antisense Oligonucleotide Therapeutics. Boca Raton, FL: CRC Press; 1995:199-221.
14. Thierry AR, Dritschilo A. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res. 1992;21:5691-5698.
15. Lavigne C, Thierry AR. Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system. Biochem Biophys Res Commun. 1997;237:566-571.
16. Kim H-J, Lee K, O'Rear JJ. A short sequence upstream of the 5' Major splice site is important for encapsidation of HIV-1 genomic RNA. Virology. 1994;198:336-340.
17. Muriaux D, Girard P-M, Bonnet-Mathoniere B, Paoletti J. Dimerization of HIV-1 Lai RNA at low ionic strength. J Biol Chem. 1995;270:8209-8216.
18. Agrawal S, Tang JY. GEM 91-an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res Dev. 1992;2:261-266.
19. Matsukura M, Zon G, Shinozuka K, et al. Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc Natl Acad Sei USA. 1989;86:42444248.
20. Ojwang JO, Buckheit RW, Pommier Y, et al. T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1995;39:2426-2435.
21. Popovic M, Read-Conole E, Gallo RC. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. Lancet. 1984;ll:1472-1473.
22. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLVIII) from patients with AIDS and pre-AIDS. Science. 1984;224:497-500.
23. Thierry AR, Lunardi-lskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. Systemic gene therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sei USA. 1995;92:9742-9746.
24. Thierry AR, Rabinovich P, Peng B, Mahan LC, Bryant JL, Gallo RC. Characterization of liposome-mediated gene delivery: expression, stability and pharmacokinetics of plasmid DNA. Gene Ther. 1997;4:226-237.
25. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods. 1988;20:309-321.
26. Gura T. Antisense has growing pains. Science. 1995;270:575-577.
27. Stein CA. Does antisense exist? Nature Medecine. 1995; 1:11191121.
28. Stein CA. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. Trends Biotechnol. 1996;14:147-149.
29. Lisziewicz J, Sun D, Metelev V, Zamecnik P, Gallo RC, Agrawal S. Long-term treatment of human immunodeficiency virus-infected cells with antisense oligonucleotide phosphorothioates. Proc Natl Acad Sei USA. 1993;90:3860-3864.
30. Agrawal S, Goodchild J, Civeira M, Sarin PS, Zamecnik PC. Nucleosides Nucleotides. 1989;8: 819-823.
31. Kinchington D, Galpin S, Jaroszewski JW, Ghosh K, Subasinghe C, Cohen JS. A comparison of gag, pol and rev antisense oligodeoxynucleotides as inhibitors of HIV-1. Antivir Res. 1992;17:5362.
32. Zelphati O, Imbach J-L, Signoret N, Zon G, Rayner B, Leserman L. Antisense oligonucleotides in solution or encapsulated in immunoliposomes inhibit replication of HIV-1 by several different mechanisms. Nucleic Acids Res. 1994;22:4307-4314.
33. Lavigne C, Thierry AR. Lipid-based delivery of combinations of antisense oligodeoxynucleotides for the in vitro inhibition of HIV-1 replication. AAPS Pharmsci. 2001 ;3:article 7. Available at: http://www.aapspharmaceutica.com/scientificjournals/pharmsci/journal/ 01_07.html. Accessed February 12, 2001.
34. Jendis J, Strack B, Volkmann S, Boni J, Moiling K. Inhibition of replication of fresh HIV type 1 patient isolates by a polypurine tractspecific self-complementary oligodeoxynucleotide. AIDS Res Hum Retroviruses. 1996; 12:1161-1168.
35. Tamamoto T, Yamamoto S, Kataoka T, Tokunaga T. Ability of oligonucleotides with certain palindromes to induce Interferon production and augment natural killer cell activity is associated with their base length. Antisense Res Dev. 1994;4:119-122.
36. Krieg A, Yi,A-K, Matson.S, et al. CpG motifs in bacterial DMA trigger direct B-cell activation. Nature. 1995;374:546-549.
37. Agrawal S, Ikeuchi T, Sun D, et al. Inhibition of human immunodeficiency virus in early infected and chronically infected cells by antisense oligodeoxynucleotide and its phosphorothioate analogue. Proc Natl Acad Sei USA. 1989;86:7790-7794.
38. Anazodo Ml, Wainberg MA, Friesen AD, Wright JA. Sequencespecific inhibition of gene expression by a novel antisense oligodeoxynucleotide phosphorothioate directed against a nonregulatory region of the human immunodeficiency virus type 1 genome. J Virol. 1995;69:1794-1801.
39. Stein CA, Cleary AM, Yakubov L, Lederman S. Phosphorothioate oligodeoxynucleotides bind to the third variable loop domain (v3) of human immunodeficiency virus type 1 gp120. Antisense Res Dev. 1993;3:9-31.
40. Yakubov L, Khaled Z, Zhang L-M, Truneh A, Vlassov V, Stein CA. Mode of interaction of oligodeoxynucleotides with recombinant sCD4. J Biol Chem. 1993;268:18818-18823.
41. Yamaguchi K, Papp B, Zhang D, AN AN, Agrawal S, Byrn RA. The multiple inhibitory mechanisms of GEM 91, a gag antisense phosphorothioate oligonucleotide, for human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 1997; 13:545-554.
42. Majumdar C, Stein CA, Cohen JS, Broder S, Wilson SH. Stepwise mechanism of HIV reverse transcriptase: Primer function of phosphorothioate oligodeoxynucleotide. Biochemistry. 1989;28:13401346.
43. Lisziewicz J, Sun D, Weichold FF, et al. Antisense oligodeoxynucleotide phosphorothioate complementary to Gag mRNA blocks replication of human immunodeficiency virus type 1 in human peripheral blood cells. Proc Natl Acad Sei USA. 1994;91:7942-7946.
44. Bordier B, Perala-Heale M, Degols G, et al. Sequence-specific inhibition of human immunodeficiency virus (HIV) reverse transcription by antisense oligonucleotides: Comparative study in cell-free assays and in HIV-infected cells. Proc Natl Acad Sei USA. 1995;92:93839387.
45. White RR, Sullenger BA, Rusconi CP. Developing aptamers into therapeutics. J Clin Invest. 2000; 106:929-934.